Novel haemodialysis (HD) treatment employing molecular hydrogen (H2)-enriched dialysis solution improves prognosis of chronic dialysis patients: A prospective observational study

[1]  A. Okawa,et al.  MRI analysis of carpal tunnel syndrome in hemodialysis patients versus non-hemodialysis patients: a multicenter case-control study , 2019, Journal of Orthopaedic Surgery and Research.

[2]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[3]  K. Maeda,et al.  Improvement of the fraction of human mercaptalbumin on hemodialysis treatment using hydrogen-dissolved hemodialysis fluid: a prospective observational study , 2016, Renal Replacement Therapy.

[4]  M. Ichihara,et al.  Beneficial biological effects and the underlying mechanisms of molecular hydrogen - comprehensive review of 321 original articles - , 2015, Medical gas research.

[5]  J. Galligan,et al.  Macrophage depletion lowers blood pressure and restores sympathetic nerve α2-adrenergic receptor function in mesenteric arteries of DOCA-salt hypertensive rats. , 2015, American journal of physiology. Heart and circulatory physiology.

[6]  S. Fukuhara,et al.  Association of blood pressure with all‐cause mortality and stroke in Japanese hemodialysis patients: The Japan dialysis outcomes and practice pattern study , 2014, Hemodialysis international. International Symposium on Home Hemodialysis.

[7]  S. Ito,et al.  Effect of a hydrogen (H2)‐enriched solution on the albumin redox of hemodialysis patients , 2014, Hemodialysis international. International Symposium on Home Hemodialysis.

[8]  Connie M. Rhee,et al.  A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival , 2013, Kidney international.

[9]  K. Iseki,et al.  Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[10]  H. Othmer,et al.  A new conceptual paradigm for the haemodynamics of salt‐sensitive hypertension: a mathematical modelling approach , 2012, The Journal of physiology.

[11]  J. Armitage,et al.  Reversal of Vascular Macrophage Accumulation and Hypertension by a CCR2 Antagonist in Deoxycorticosterone/Salt-Treated Mice , 2012, Hypertension.

[12]  S. Ito,et al.  A novel bioactive haemodialysis system using dissolved dihydrogen (H2) produced by water electrolysis: a clinical trial. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  Kuo-Chin Huang,et al.  Electrolysed-reduced water dialysate improves T-cell damage in end-stage renal disease patients with chronic haemodialysis. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  K. Iseki,et al.  2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease , 2010, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[15]  S. Ito,et al.  Biological Effects of Electrolyzed Water in Hemodialysis , 2009, Nephron Clinical Practice.

[16]  S. Ito,et al.  Less‐oxidative hemodialysis solution rendered by cathode‐side application of electrolyzed water , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[17]  Yasuo Katayama,et al.  Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals , 2007, Nature Medicine.

[18]  N. Vaziri,et al.  Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. , 2007, Kidney international.

[19]  C. Chien,et al.  Electrolyzed-reduced water reduced hemodialysis-induced erythrocyte impairment in end-stage renal disease patients. , 2006, Kidney international.

[20]  J. Aronson,et al.  What is a clinical trial? , 2004, British journal of clinical pharmacology.

[21]  Kuo-Chin Huang,et al.  Reduced hemodialysis-induced oxidative stress in end-stage renal disease patients by electrolyzed reduced water. , 2003, Kidney international.

[22]  Peter Stenvinkel,et al.  The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.

[23]  P. Flakoll,et al.  Inflammatory signals associated with hemodialysis. , 2002, Kidney international.

[24]  I. Ebihara,et al.  INTERLEUKIN-6 GENE EXPRESSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM PATIENTS UNDERGOING HEMODIALYSIS OR CONTINUOUS AMBULATORY PERITONEAL DIALYSIS , 2000, Renal failure.

[25]  C. Wanner,et al.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.

[26]  A. Levey,et al.  "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. , 1998, Kidney international.

[27]  M. Levitt.  Volume and composition of human intestinal gas determined by means of an intestinal washout technic. , 1971, The New England journal of medicine.